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COSTS OF INSULIN GLARGINE AND INSULIN DETEMIR IN INTENSIVE 
INSULIN THERAPY FOR TYPE 1 DIABETES MELLITUS IN ARGENTINA:  
A PROBABILISTIC MODEL
Pichon-Riviere A1, Caporale JE1, von Schulz-Hausmann C2, Augustovski FA1
1Institute for Clinical Effectiveness and Health Policy (IECS), Ciudad Autónoma de Buenos 
Aires, Buenos Aires, Argentina, 2Sanoﬁ-aventis Argentina, Buenos Aires, Argentina
OBJECTIVES: To estimate and compare costs of treatment in a type 1 diabetic popula-
tion (T1DM) using intensive insulin therapy of insulin glargine (IG) and detemir (ID) 
with a 26 week time horizon, from insurers perspective in Argentina (government and 
union-based). METHODS: Clinical and efﬁcacy parameters and their distributions 
were based on Pieber’s article (2007), a 26-week open-label multicenter randomized 
treat-to-target trial which compared clinical outcomes of IG and ID, each in combina-
tion with insulin aspart, in T1DM patients. Resource use and cost values, and their 
distributions, were obtained from Argentinean literature, tariffs, databases, experts’ 
opinion and the international literature. Variability was incorporated in ﬁnal body 
weight; average ﬁnal doses of ID, IG and average dose of insulin aspart; discount over 
retail prices of insulins; needles and strips unit costs; and severe hypoglycemia risk. 
We undertook a probabilistic sensitivity analysis (PSA) based on Montecarlo simula-
tions with 10,000 iterations including correlation among selected parameters. We 
computed rank correlation between parameters and results in order to evaluate their 
contribution to global uncertainty. Costs are expressed in Argentinean pesos 2009 
(1US$  3.45ARG$). RESULTS: The mean cost was $3913 for IG and $4382 for ID, 
implying 11% total costs savings with IG ($469). Insulin cost was 11% lower with 
IG ($2449 vs $2741) explaining 62% of the total savings. In 69.9% of the iterations 
IG resulted less costly. Main factors inﬂuencing this variability were the average daily 
dose requirement of ID, IG and insulin aspart, together they explained 73.1% (ID 
group) and 20.4% (IG group) of the variance. Finally, bootstrapping techniques were 
used and conﬁrmed the accuracy and reliability of our results. CONCLUSIONS: Our 
analysis shows that in Argentina, Insulin Glargine could imply a cost saving of around 
10% compared to Insulin Detemir in T1DM intensive insulin therapy. Sensitivity 
analyses conﬁrmed the robustness of our results.
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COSTS OF DISEASE COMPLICATIONS RELATED TO DM2 IN MEXICO:  
A SYSTEMATIC REVIEW
Uc-Coyoc R1, López RJ2, Anaya P2, Elias-Lopez JI1, Juarez-Garcia A1
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OBJECTIVES: Assessing the costs of complications is relevant to estimate the overall 
economic consequences of type 2 diabetes mellitus. The purpose of this study is to 
review the different cost estimation of four relevant complications related to DM2 in 
the literature among the public health institutions. METHODS: A systematic review 
was performed to retrieve information on costs for myocardial infraction, stroke, 
amputation and end stage renal disease (ESRD). For each complication, the terms 
costs, diabetes type 2, economic burden, health care, were searched in Pub Med, OVID 
and Medic Latina from 2000 to 2008. Costs disease estimations are from public health 
institutions such as IMSS, ISSSTE and SSA. Costs are expressed in American dollars 
at an exchange rate of $ 15.2 Mexican pesos per dollar. RESULTS: Among institu-
tions, the highest estimated cost is attributed to ESRD with a range of annual costs 
from $5,737 to $ 23,526 for SSA and IMSS respectively. The most striking annual 
cost difference was found for stroke with a cost at SSA of $1,561 and $ 12,515 at 
IMSS. Within institutions, the estimated costs for myocardial infraction at IMSS vary 
considerably ranging from $2,670 to $13,724. Estimation on amputation costs was 
very limited, a study at IMSS shows that the costs depends on the type of amputation 
required ranging from $5,938 to $13,188 for primary and secondary amputation 
respectively. CONCLUSIONS: The studies show that the estimation costs of disease 
complications related to DM2 among and within public institutions vary widely. These 
huge differences can be attributed to a variety in disease treatment patterns among 
institutions, as well as, the use of non-standardized methodological costs techniques. 
As a result, further research is needed in order to get a consensus on the costs of DM2 
and its complications. This information is indispensable for the ﬁnancial planning of 
health care resources.
PDB3
RESOURCE USE AND DIRECT MEDICAL COSTS ASSOCIATED TO 
ACROMEGALY TREATMENT UNDER THE BRAZILIAN PUBLIC HEALTH 
CARE SYSTEM PERSPECTIVE
Teich V, Takemoto M, Bahia L
MedInsight, Rio de Janeiro, Brazil
OBJECTIVES: To estimate the resource use and direct medical costs associated with 
acromegaly treatment under the Brazilian public health care system (BPS) perspective. 
METHODS: Expert opinion was used because neither the published literature nor 
national databases contain adequate information on the resource use and costs associ-
ated with acromegaly in Brazil. The role of the expert panel was two-fold: to validate 
the acromegaly treatment algorithm and estimate the resource use associated with 
treatment. The panel was comprised of four endocrinologists, considered experts in 
the ﬁeld and who work in the BPS. Only direct medical costs were considered in the 
analysis, including medications, outpatient visits, surgery, radiation therapy and acro-
megaly-related tests and procedures. Unit costs were obtained from BPS databases. 
RESULTS: The estimated distribution of patients between health states was 33% for 
adequately controlled disease, 34% uncontrolled disease despite drug therapy, 8% 
uncontrolled disease without drug therapy and 24% cure. The mean estimated cost 
per patient with adequately controlled acromegaly in 5 years was R$135,039 
(US$96,457; 2005 PPP index 1USD  1.4BRL). Among patients with uncontrolled 
disease, those undergoing drug therapy represent a mean 5-year cost per patient of 
R$135,989 (US$97,135) and the mean cost associated with patients without drug 
therapy was R$6684 (US$4775). For cured patients, costs were incurred only for 
treatment of adenoma and exams in the ﬁrst year, corresponding to total costs of 
R$4292 (US$ 3066). Medications were the largest contributor to overall cost, corre-
sponding to 81% of total costs. The chronic complications of long-standing disease 
increase costs signiﬁcatively, but were not included in the analysis, contributing to the 
absence of signiﬁcant cost differences between controlled and uncontrolled patients. 
CONCLUSIONS: Patients with acromegaly represent an average cost of R$93,069 in 
5 years to the public health care system, considering a weighted average of patients 
in all possible health states.
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COST OF TYPE 2 DIABETES COMPLICATIONS IN MEXICO
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OBJECTIVES: Estimate the direct medical costs of type 2 diabetes—related (T2D) 
complications in Mexican Ministry of Health’s public hospitals. METHODS: A com-
plication—speciﬁc survey was designed to estimate resource utilization and procedures 
performed for T2D—related complications reported in the CORE model under the 
Mexican Ministry of Health (MoH) perspective. Three public—institution specialists 
were interviewed per complication. Costs were obtained from MoH hospitals ofﬁcial 
cost report for 2004 and discounted at a 3% annual rate. Only costs for Year 1 
and 2 were considered. Results are shown as maximum/minimum costs for each 
complication in Mexican pesos (MXN). Cost of medications, prosthesis and 
cardiovascular markers were excluded. RESULTS: The costs for cardiovascular 
complications were $121,496/120,157 (myocardial infarction), $179,680/175,818 
(angina), $117,642/113,517 (congestive heart failure), $117,539/105,902 (stroke), 
$99,750/96,418 (peripheral vascular disease); ophthalmologic complications 
cost $42,852/42,593 (retinal photocoagulation), $14,318/14,318 (blindness), 
$124,370/124,370 (cataract operation); other complications cost $530,318/521,384 
(chronic kidney failure), $17,849/16,692 (neuropathy), $133,048/132,799 (non-
infected ulcer), $179,827/178,839 (infected ulcer), $96,411/96,411 (gangrene), 
$156,038/155,300 (foot amputation), $90,632/90,632 (ketoacidosis) and $69,208/ 
69,160 (complicated hypoglycemia). CONCLUSIONS: This analysis showed that the 
most expensive T2D related complications for the Mexican health system are chronic 
kidney failure, infected ulcers and angina. As diabetes prevalence rate is increasing 
rapidly in Mexico, public institutions should adopt cost—effective clinical strategies 
to avoid the ﬁnancial burden of future T2D—related clinical complications.
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ESTIMACIÓN DEL COSTO ASOCIADO A LA PÉRDIDA DE 
PRODUCTIVIDAD POR MORTALIDAD ATRIBUIBLE A LA DIABETES  
EN ARGENTINA
Elgart J, Caporale JE, Pﬁrter G, Gonzalez L, Siri F, Gagliardino JJ
CENEXA—Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
OBJECTIVOS: Estimar la pérdida de productividad por mortalidad atribuible a la 
diabetes en Argentina, discriminados por provincia y rango etáreo (15–79 años) para 
el año 2005. METODOLOGÍAS: El cálculo implica: 1) Ajustar el número de muertes 
por diabetes informadas por el Ministerio de Salud de la Nación; 2) Estimar las 
muertes por IAM y ACV atribuibles a la diabetes; 3) Estimar el Valor Estadístico de 
una Vida (VEV) por región y rango etario utilizando el método del Capital Humano; 
4) Asignar valores monetarios al total de muertes atribuibles a la diabetes por provin-
cia y rango etario. RESULTADOS: Estimamos 20,248 muertes atribuibles a la diabe-
tes en Argentina. La mayoría de ellas ocurridas en los rangos etarios superiores. El 
valor monetario promedio perdido por muerte prematura es de AR$24,262. La 
pérdida de productividad por muerte prematura atribuible a la diabetes en Argentina 
supera los AR$ 491 millones. El mayor costo se registró en Buenos Aires (AR$ 267 
millones), luego la Ciudad Autónoma de Buenos Aires (AR$ 44 millones), Santa Fé 
(AR$ 35 millones) y Córdoba (AR$ 33 millones), debido en parte a los mayores 
ingresos registrados en estas provincias. Ajustando por población, Santa Cruz registra 
el mayor costo individual (AR$ 30.5), luego Buenos Aires (AR$ 28.4), San Luís 
(AR$ 24.0) y Tierra del Fuego (AR$ 21.7). CONCLUSIONES: En Argentina la 
pérdida de productividad por mortalidad atribuida a la diabetes genera altos costos 
con importantes diferencias regionales. Las muertes son mayoritariamente causadas 
por complicaciones cardiovasculares (IAM y ACV). Estas estimaciones son conserva-
doras debido al subregistro de diabetes como causa subyacente de muerte. Este estudio 
identiﬁca un componente adicional del costo de la diabetes, que por su magnitud, 
debería considerarse en toda evaluación económica de implementación de programas 
de prevención.
